Relevant bibliographies by topics / (HIV-1)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic '(HIV-1)'

Author: Grafiati
Published: 4 June 2021
Last updated: 14 September 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '(HIV-1).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "(HIV-1)"

1

Tsukada, Kunihisa. "1. HIV-1 Infection." Nihon Naika Gakkai Zasshi 96, no. 11 (2007): 2442–49. http://dx.doi.org/10.2169/naika.96.2442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Asang, Corinna, Hans-J. Laws, Ortwin Adams, Jürgen Enczmann, Cornelia Feiterna-Sperling, Gundula Notheis, Bernd Buchholz, Arndt Borkhardt, and Jennifer Neubert. "HIV-1 seroreversion in HIV-1-infected children." AIDS 28, no. 4 (February 2014): 543–47. http://dx.doi.org/10.1097/qad.0000000000000065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hansasuta, Pokrath, and Sarah L. Rowland-Jones. "HIV-1 transmission and acute HIV-1 infection." British Medical Bulletin 58, no. 1 (September 1, 2001): 109–27. http://dx.doi.org/10.1093/bmb/58.1.109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Curran, Kathryn, Jared M. Baeten, Thomas J. Coates, Ann Kurth, Nelly R. Mugo, and Connie Celum. "HIV-1 Prevention for HIV-1 Serodiscordant Couples." Current HIV/AIDS Reports 9, no. 2 (March 14, 2012): 160–70. http://dx.doi.org/10.1007/s11904-012-0114-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Loussert-Ajaka, I., F. Brun-Vézinet, F. Simon, T. D. Ly, M. L. Chaix, S. Saragosti, A. M. Couroucé, and D. Ingrand. "HIV-1/HIV-2 seronegativity in HIV-1 subtype 0 infected patients." Lancet 343, no. 8910 (June 1994): 1393–94. http://dx.doi.org/10.1016/s0140-6736(94)92524-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fujiwara, Mamoru, and Masafumi Takiguchi. "HIV-1–specific CTLs effectively suppress replication of HIV-1 in HIV-1–infected macrophages." Blood 109, no. 11 (June 1, 2007): 4832–38. http://dx.doi.org/10.1182/blood-2006-07-037481.

Full text
Abstract:
AbstractBoth CD4+ T cells and macrophages are major reservoirs of HIV-1. Previous study showed that HIV-1–specific cytolytic T lymphocytes (CTLs) hardly recognize HIV-1–infected CD4+ T cells because of Nef-mediated HLA class I down-regulation, suggesting that HIV-1 escapes from HIV-1–specific CTLs and continues to replicate in HIV-1–infected donors. On the other hand, the CTL recognition of HIV-1–infected macrophages and the effect of Nef-mediated HLA class I down-regulation on this recognition still remain unclear. We show a strong HIV-1 antigen presentation by HIV-1–infected macrophages. HIV-1–specific CTLs had strong abilities to suppress HIV-1R5 virus replication in HIV-1–infected macrophages and to kill HIV-1R5–infected macrophages. Nef-mediated HLA class I down-regulation minimally influenced the recognition of HIV-1–infected macrophages by HIV-1–specific CTLs. In addition, HIV-1–infected macrophages had a stronger ability to stimulate the proliferation of HIV-1–specific CTLs than HIV-1–infected CD4+ T cells. Thus, the effect of Nef-mediated HLA class I down-regulation was less critical with respect to the recognition by HIV-1–specific CTLs of HIV-infected macrophages than that of HIV-1–infected CD4+ T cells. These findings support the idea that the strong HIV-1 antigen presentation by HIV-1–infected macrophages is one of the mechanisms mediating effective induction of HIV-1–specific CTLs in the acute and early chronic phases of HIV-1 infection.
APA, Harvard, Vancouver, ISO, and other styles
7

Bradbury, Jane. "HIV-1-resistant individuals may lack HIV-1 coreceptor." Lancet 348, no. 9025 (August 1996): 463. http://dx.doi.org/10.1016/s0140-6736(05)64540-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shen, R., M. Raska, D. Bimczok, J. Novak, and P. D. Smith. "HIV-1 Envelope Glycan Moieties Modulate HIV-1 Transmission." Journal of Virology 88, no. 24 (October 1, 2014): 14258–67. http://dx.doi.org/10.1128/jvi.02164-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zeytinoğlu, Ayşın, Münevver Kayın, İmre Altuğlu, Deniz Gökengin, and Rüçhan Sertöz. "İki Anti-HIV Doğrulama Testinin Karşılaştırılması: Rekombinant HIV 1/2 “Line İmmunoassay” ve Geenius HIV 1/2 Doğrulama Testi." Mikrobiyoloji Bulteni 54, no. 4 (October 15, 2020): 613–18. http://dx.doi.org/10.5578/mb.69786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Joseph, J. Mehsen. "Testing (HIV-1)." Infection Control and Hospital Epidemiology 12, no. 8 (August 1991): 474–75. http://dx.doi.org/10.2307/30146877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "(HIV-1)"

1

Swan, Christina Heidi. "HIV-1 intracellular immunization via HIV-1 derived vector delivered genetic mechanisms." Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2006. http://wwwlib.umi.com/cr/ucsd/fullcit?p3204640.

Full text
Abstract:
Thesis (Ph. D.)--University of California, San Diego, 2006.
Title from first page of PDF file (viewed April 4, 2006). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Wa. "The evolution of HIV-1 and HIV-2." Thesis, University College London (University of London), 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.405605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Létourneau, Sven C. "HIV-1 vaccine development." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Haddrick, Malcolm. "HIV-1 RNA dimerisation." Thesis, University of Leicester, 1996. http://hdl.handle.net/2381/35383.

Full text
Abstract:
Genomic RNA isolated from retroviral particles is a dimer composed of two identical strands. A region called the dimer linkage site close to the 5' end of the RNA may be involved in forming the dimer. Several models for the formation of the HIV-1 genomic RNA dimer have been proposed. In the "kissing loop" model, dimerisation results from base pairing between homologous sequences in an RNA stem loop. In the guanine tetrad model interstrand guanine contacts form the dimer. Mutations have been made preventing the dimerisation of subgenomic RNAs in vitro by these mechanisms. To prevent the "kissing loop" dimer forming the complementary loop sequence 711GCGCGC716 was changed to 711AAACGC716. To prevent the guanine tetrad dimer forming residue G819 was changed to U. These mutations were introduced into a clone of HIV-lNL4-3 separately and collectively. All three clones produced infectious virions. Dimeric RNA with similar thermal stabilities was isolated from viruses containing either the single or the double mutations. The results suggest that sequences involved in forming a guanine tetrad are not important for HIV-1 RNA dimerisation. In contrast sequences involved in forming a kissing loop complex are not absolutely required, but are important in forming a stable HIV-1 RNA dimer.
APA, Harvard, Vancouver, ISO, and other styles
5

Davis, Katie L. "Analysis of HIV-1 variable loop 3-specific neutralizing antibody responses by HIV-2/HIV-1 envelope chimeras." Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2008. https://www.mhsl.uab.edu/dt/2009r/davis.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Duvall, Melody Gayle. "HIV-specific cellular immune responses in HIV-1 and HIV-2 infection." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.441307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McIntyre, Glen J. Biotechnology &amp Biomolecular Sciences Faculty of Science UNSW. "Antiviral shRNA (for HIV-1)." Awarded by:University of New South Wales, 2006. http://handle.unsw.edu.au/1959.4/35215.

Full text
Abstract:
Human Immunodeficiency Virus type I (HIV-1) is an RNA virus that causes Acquired Immunodeficiency Syndrome (AIDS). Gene therapy is a new treatment paradigm that aims to modify the patient???s cells with therapeutic agents to reduce viral replication and disease progression. A recently discovered technology with potential application in gene therapy for HIV-1 is the RNA interference (RNAi) pathway; a natural gene suppression mechanism where a 19 ??? 21 bp dsRNA trigger prevents the translation of complementary target RNAs. The RNAi pathway can be harnessed artificially with short hairpin RNAs (shRNAs or hairpins); expressed RNA transcripts that fold into ???hairpin??? configurations by virtue of selfcomplementary regions separated by a short ???loop??? sequence. The aim of this project was to use pre-clinical models to investigate shRNA design, construction, screening and coexpression for potential use as an anti-HIV-1 therapeutic agent. A PC2-rated assay using multiple fluorescent reporters was developed to screen shRNAs for anti-HIV-1 suppressive activity, simultaneously measuring, and distinguishing, between target-specific and nonspecific shRNA activities. Phi29 DNA polymerase was used to modify the primer extension method for constructing shRNA vectors, increasing its efficiency whilst maintaining its cost effectiveness. A novel sequencing procedure using a restriction enzyme loop sequence was developed, which allowed the sequence of all shRNA vectors to be confirmed at highthroughput automated sequencing facilities. A comprehensive study of hairpin design factors showed that whilst shRNA stem length could affect processing and activity, sequence composition was the critical determinant of suppressive activity. Using the screening and construction methods developed here, many hairpins were designed and tested with at least one highly active hairpin found for each HIV-1 gene. Pre-existing and novel shRNA co-expression strategies were successfully used to co-express up to 4 hairpins to theoretically counter the emergence of viral escape mutants. Overall, this work has shown that expressed shRNAs are potentially suitable to treat HIV-1, since highly active shRNAs can be designed against all HIV-1 genes, shRNA vectors can be efficiently constructed, shRNA activities can be effectively screened and shRNAs can be combined to suppress simultaneously multiple targets.
APA, Harvard, Vancouver, ISO, and other styles
8

Archer, John Patrick. "The diversity of HIV-1." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.495044.

Full text
Abstract:
The phylogeny of the Human Immunodeficiency Virus type 1 (HIV-1) is characterized by extensive diversity. However when it comes to the persistence of the virus not all of this diversity is relevant. In this thesis I show that the significance of diversity, both In relation to epidemiology and vaccine design, varies within and between the HIV-1 groups. The substructure present within group O and at the center of the group M pandemic was observed to be similar to that found on random tree topologies, whereas the substructure present within globally sampled group M strains was significantly different.
APA, Harvard, Vancouver, ISO, and other styles
9

Brown, D. E. "Antisense approaches towards HIV-1." Thesis, University of Cambridge, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.596956.

Full text
Abstract:
Several forms of therapeutic antisense molecule have been developed. These include small interfering RNAs (siRNAs), short hairpin (shRNAs) and longer single stranded antisense RNAs. In this study, steric blocking RNA oligonucleotides (ONs) and their analogues were investigated. The packaging process of HIV-1 is highly specific and involves an interaction between the Gag protein and a conserved sequence that is only present on genomic viral RNA. This region is known as Ψ and comprises four stem loops (SL1-4), within which SL3 is a high affinity binding site for Gag. Deletion of SL3 severely reduces viral packaging. High affinity ONs targeted to Ψ inhibited Gag binding in vitro and confirmed SL3 as the major packaging determinant SL2 was also shown to influence Gag binding, but to a lesser extent. HIV-1 replication was inhibited following cellular delivery of SL3 targeted ONs. An ON targeted to trans-activating response region (TAR) of HIV-1 also showed antiviral activity in these assays. From those tested, mixmer ONs consisting of 2’-O-Methyl and locked nucleic acid analogues (2’Ome/LNA) showed significant and sequence-specific inhibition of viral replication. Having identified target sequences, viral vectors were developed to deliver expressed forms of these in vivo. A minimal lentiviral vector based on HIV-2 was produced with reduced homology to packaging constructs. This demonstrated efficient gene transfer.
APA, Harvard, Vancouver, ISO, and other styles
10

Heap, Caroline J. "Analysis of HIV-1 neutralisation." Thesis, University of Warwick, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.409953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "(HIV-1)"

1

Graham, David R. M., and David E. Ott, eds. HIV-1 Proteomics. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6542-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Neamati, Nouri, ed. HIV-1 Integrase. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Silvestri, Guido, and Mathias Lichterfeld, eds. HIV-1 Latency. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02816-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Xiaoyi. Antibodies mediating anti-HIV-1 ADCC in HIV-1 infection. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

A, Sparano Joseph, ed. HIV & HTLV-1 associated malignancies. Boston: Kluwer Academic Publishers, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

), Harvard College (1780, and United States. Army Medical Research and Materiel Command, eds. Interactions of HIV-1 and HIV-2 in West Africa. Fort Detrick, Maryland: U.S. Army Medical Research and Materiel Command, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kuan-Teh, Jeang, ed. HIV-1: Molecular biology and pathogenesis. San Diego, Calif: Academic Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Torbett, Bruce E., David S. Goodsell, and Douglas D. Richman, eds. The Future of HIV-1 Therapeutics. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18518-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harrison, Coral Teresa. Spermicides and HIV Type 1 transmission. Manchester: University of Manchester, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

DeLorenzo, Lori A. HIV/AIDS: A 1-hour overview. 4th ed. South Easton, MA: Western Schools Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "(HIV-1)"

1

O’Connor, Shelby L. "HIV-1 Sequencing." In HIV-1 Proteomics, 59–76. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6542-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

De Clercq, Erik. "HIV Life Cycle: Targets for Anti-HIV Agents." In HIV-1 Integrase, 1–14. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hare, Stephen, Alan Engelman, and Peter Cherepanov. "Structural aspects of Lentiviral Integrase-LEDGF Interaction." In HIV-1 Integrase, 131–40. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Katz, Richard A., René Daniel, and Anna Marie Skalka. "Host Factors that affect Provirus Stability and Silencing." In HIV-1 Integrase, 141–50. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Christ, Frauke, Katrien Busschots, Jelle Hendrix, Melissa McNeely, Yves Engelborghs, and Zeger Debyser. "Assays for Evaluation of HIV-1 Integrase Enzymatic Activity, DNA Binding, and Cofactor Interaction." In HIV-1 Integrase, 151–63. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Neamati, Nouri. "HIV-1 Integrase Inhibitor Design: Overview and Historical Perspectives." In HIV-1 Integrase, 165–96. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Egbertson, Melissa S., Neville J. Anthony, and Vincenzo Summa. "HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir." In HIV-1 Integrase, 197–229. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shinkai, Hisashi, Motohide Sato, and Yuji Matsuzaki. "Elvitegravir: Novel Quinolone HIV-1 Integrase Strand Transfer Inhibitor." In HIV-1 Integrase, 231–38. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fardis, Maria, Haolun Jin, Xiaowu Chen, Manuel Tsiang, James Chen, Choung Kim, and Matthew Wright. "Conformationally Constrained Tricyclic HIV Integrase Inhibitors." In HIV-1 Integrase, 239–54. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Garvey, Edward P., and Benjamin Schwartz. "Slow-Onset Kinetics of HIV Integrase Inhibitors and Proposed Molecular Model." In HIV-1 Integrase, 255–63. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118015377.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "(HIV-1)"

1

Abdullah, Muhammad, Seher Ansar Khawaja, and Muhammad Farooq. "HIV-1 Protease Cleavages." In 2021 International Conference on Innovative Computing (ICIC). IEEE, 2021. http://dx.doi.org/10.1109/icic53490.2021.9692978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Amaral, Marina Henriques, GIOVANNA XAVIER TOLEDO, LÍVIA SANTIAGO E. SILVA, and MARINA MEDEIROS SOARES. "HIV-1 PEDIÁTRICO: COMO PREVINIR?" In III Congresso Brasileiro de Saúde Pública On-line. Revista Multidisciplinar em Saúde, 2023. http://dx.doi.org/10.51161/conbrasp2023/27225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schramm, W., L. G. Gürtler, H. Pohlmann, I. Weigel, J. Eberie, and F. Deinhardt. "INCIDENCE OF HIV-1 AND HIV-2 ANTIBODIES IN HEMOPHILIACS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644142.

Full text
Abstract:
The presence of antibodies to HIV-1 (anti-HIV-1) was tested in 167 hemophiliacs surveyed and treated at Munich hemophilia center. Increasing numbers of HIV infected patients were observed in the years 1981 to 1986 from 0% to 51,5% (86 positive patients in January 1987 of 167 followed patients). Most of the seroconver-sions occured between 1982 and 1984. The 150 clinically severe affected hemophiliacs (F-VIII-levels up to 5% and need of replacement therapy) showed positive HIV-test results in 55,3% (83 patients) and negative results in 44,7% (67 patients). 5 patients died since 1981, one because of AIDS. 17 patients were not seen since 1984, 14 of those belong to the severly affected group, 12 of them were negative. Since spring 1985 only heat or chemically treated clotting factor preparations are used for substitution. Despite this still 5 seroconversions were observed. Two may be attributed to the use of a preparation heat inactivated in dry state, this preparation is no longer used. The other 3 seroconversions possibly were caused by an occasional use of an noninactivated preparation in the beginning of the change to inactivated clotting factor preparations. 38 of the anti-HIV-1 positive sera were tested for the presence of HIV-2 antibodies also. The methods were ELISA,immunofluorescence and immunoblot. HIV-2 (LAV-2) for these tests was kindly provided by L. Montagnier. Antibodies specific for HIV-2 antigens were not detected, but crossreactions were observed between anti-HIV-1 with HIV-2 antigens particularly epitopes on HIV-2-p27.The data indicate that the use of adequately inactivated clotting factors can prevent infection of hemophilia patients by this route and that HIV-2 was not present in the clotting factor preparations used for the substitution of this group of patients. The incidence of full blown AIDS since 1981 in our group of hemophiliacs is still low (1,2%).
APA, Harvard, Vancouver, ISO, and other styles
4

Chandra, Sushil, and Ahsan Zaigam Rizvi. "Wavelet Analysis of HIV-1 Genome." In 2009 International Association of Computer Science and Information Technology - Spring Conference. IEEE, 2009. http://dx.doi.org/10.1109/iacsit-sc.2009.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xu, Chang. "Advances in treating HIV-1 infections." In International Conference on Biological Engineering and Medical Science (ICBIOMed2022), edited by Gary Royle and Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Paul, Sinu, and Helen Piontkivska. "Highly conserved and associated HIV-1 CTL and T-Helper epitopes in global HIV-1 population." In the First ACM International Conference. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1854776.1854899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nouri, Reza, Yuqian Jiang, Anthony J. Politza, Xiaojun Lance Lian, and Weihua Guan. "Digital CRISPR-based quantification of HIV-1." In 2022 IEEE Sensors. IEEE, 2022. http://dx.doi.org/10.1109/sensors52175.2022.9967104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barbosa, Karen Eduarda, and Jorge Alexandre Nogueira Santos. "ANÁLISE DO PAPEL DA ENZIMA HIV- 1 PROTEASE NO CICLO REPLICATIVO DO HIV." In I Congresso Nacional de Microbiologia Clínica On-Line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/1197.

Full text
Abstract:
Introdução: De acordo com os dados do boletim epidemiológico do Ministério da Saúde (2020), foram notificados 342.459 casos de infecção pelo vírus HIV no Brasil, entre os períodos de junho de 2007 a junho de 2020, demonstrando uma grande incidência da doença no país. Responsável pela depleção de linfócitos TDC4 +, o tratamento disponível consiste na terapia antirretroviral (HAART), baseada em inibidores de proteases entre os quais destaca-se a HIV-1 protease. Essa enzima é responsável pelo desenvolvimento do vírus, se constituindo num importante alvo farmacológico para o tratamento da AIDS. Objetivos: Nesse contexto, esse trabalho fará uma análise do papel da HIV-1 protease no ciclo de replicação do HIV. Materiais e Métodos: O presente trabalho tratou-se de um estudo descritivo que fez uso da base de dados do portal PUBMED, por meio da combinação das seguintes palavras chaves: HIV-1 protease, replication e AIDS. Filtrados os resultados de 2017 a 2021, obteve-se um total de 13 artigos para a recuperação dos dados. Resultados: O capsídeo viral possui as enzimas virais integrase, transcriptase reversa e proteases associadas ao genoma. A HIV-1 protease é um homodímero formado por 2 monômeros com 99 resíduos cada, e com o sítio formado pela tríade: Asp-25, Thr-26 e Gli-27. Localizada acima do sítio ativo da enzima, há a região flat que se abre para a entrada do substrato e também se fecha sobre ela quando complexada à substância. Ressalta-se que essa região também é importante para garantir a estabilidade da enzima. A clivagem das poliproteínas gag e pol, responsáveis pela formação das proteínas estruturais do vírus, ocorre quando dois resíduos de aspartato ligam-se a uma molécula de água e promovem a hidrólise do substrato. Tal clivagem permite um rearranjo das cadeias que agora se tornam funcionais e originam partículas infecciosas que poderão ser liberadas no citoplasma e progredir com a infecção. Conclusões: Essa enzima é relevante para o entendimento do ciclo replicativo do HIV, uma vez que se relaciona com a produção de proteínas virais funcionais. Sua inibição dá origem a partículas virais imaturas e por isso a enzima se constitui em um dos alvos para inibição.
APA, Harvard, Vancouver, ISO, and other styles
9

Zhao, Xue Zhi, Mathieu Métifiot, Kasthuraiah Maddali, Steven J. Smith, Christophe Marchand, Stephen H. Hughes, Yves Pommier, and Terrence R. Burke, Jr. "HIV Viral Protein R (Vpr)-Derived Peptides Designed as HIV-1 Integrase Photoaffinity Ligands." In The Twenty-Third American and the Sixth International Peptide Symposium. Prompt Scientific Publishing, 2013. http://dx.doi.org/10.17952/23aps.2013.084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Masso, Majid. "Sequence-based prediction of HIV-1 coreceptor usage." In the 2nd ACM Conference. New York, New York, USA: ACM Press, 2011. http://dx.doi.org/10.1145/2147805.2147841.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "(HIV-1)"

1

Kanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada367779.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, July 1997. http://dx.doi.org/10.21236/ada329299.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kanki, Phyllis J. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada416999.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Weislow, Owen S. Support for HIV-1 Intervention Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada335164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pham, Christian. Monoclonal Antibodies Against HIV-1 Induced Acquired Immunodeficiency Syndrome. Ames (Iowa): Iowa State University, May 2022. http://dx.doi.org/10.31274/cc-20240624-1023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ratner, Lee. Development of an RNA Assay to Access HIV-1 Latency. Fort Belvoir, VA: Defense Technical Information Center, April 1991. http://dx.doi.org/10.21236/ada251728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Celum, Connie, and Thomas Inui. Indeterminate HIV-1 Western Blots: Etiology, Natural History and Psychological Reactions. Fort Belvoir, VA: Defense Technical Information Center, September 1991. http://dx.doi.org/10.21236/ada247531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bryer, Alexander, Tyler Reddy, Edward Lyman, and Juan Perilla. MD Simulations of Full-Scale HIV-1 Lipid Envelope on LANL Grizzly Supercomputer. Office of Scientific and Technical Information (OSTI), April 2021. http://dx.doi.org/10.2172/1778751.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Djimeu, Eric W., and Eleanor G. Dickens. Treatment as prevention: a replication study on early antiretroviral therapy initiation and HIV-1 transmission. International Initiative for Impact Evaluation (3ie), June 2020. http://dx.doi.org/10.23846/rps0024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Trachunthong, Deondara, Suchintana Chumseng, Worrayot Darasawang, and Mathuros Tipayamongkholgul. Risk Factors and National Burden of Selected Noncommunicable Diseases in People Living with HIV: Systematic Review, Meta-Analysis and, Disability-Adjusted Life Years protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0018.

Full text
Abstract:
Review question / Objective: 1. Are the prevalence/incidence of four major groups of NCDs including MetS, DM, CVD, and CKD different among adults with and without HIV infection? 2. Are there relationships between HIV status, ART (ART use, short and long-term effects of ART), traditional risk factors (BMI), and the development of four major NCDs? 3. Does the trend of NCDs burden attributable to HIV in Thailand increase according to the time? Information sources: 1. Electronic databases: the following databases will be searched: PubMed/Medline, Scopus, Embase, Cochrane Library Thai journals online (ThaiJO), Thai digital collection (TDC), Thai journal index (TJI), and Thai-journal citation index (TCI). 2. Authors or experts in the field will be contacted through emails for any relevant data, results and information.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '(HIV-1)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography